about
Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapyMDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine TumoursActivation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis.Isothermal multiple displacement amplification: a methodical approach enhancing molecular routine diagnostics of microcarcinomas and small biopsies.Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.Differential regulation of monocarboxylate transporter 8 expression in thyroid cancer and hyperthyroidism.Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString).Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.[Inflammation of the parathyroid glands].Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinomaDifferent micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study.ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.FFPE tissue as a feasible source for gene expression analysis--a comparison of three reference genes and one tumor marker.Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.[Inflammatory diseases of the thyroid gland].[Molecular pathogenesis of thyroid tumors].[Clinical importance of thyroid gland cytology].[Medullary thyroid carcinoma].[Intraoperative frozen sections of the thyroid gland].[Thyroid C cells and their pathology: Part 2: Medullary thyroid carcinoma].[Thyroid C cells and their pathology: Part 1: normal C cells, - C cell hyperplasia, - precursor of familial medullary thyroid carcinoma].HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.[Hyalinizing trabecular tumor of the thyroid. An overcautious designation of a benign thyroid tumour?].Endoscopic submucosal dissection for rectal neoplasia extending to the dentate line: European experience[MicroRNA profiles in fine needle biopsy of the thyroid][Rapid on-site evaluation (ROSE) in cytological diagnostics of pulmonary and mediastinal diseases][Familial thyroid carcinomas]Q85217666[Role of pretherapeutic biomarkers in lung cancer with special regards to bronchoscopic procedures]Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation
P50
Q27852901-ECF088EF-0149-425D-AFF0-C2879F5735D7Q27853125-882E97AB-59F7-42D1-B6C0-D775BC2B489FQ28246704-CE5B3E85-433E-466C-859D-96808C9C1927Q33789403-E16B2346-8591-4882-8AE3-526B9CB71F1DQ35230721-556E0457-56DD-4270-BF94-2F8D7DA4B7DCQ36413013-2BF8074C-24E3-4D04-A911-75A0A7C63C44Q38701429-2C73B690-0B0C-4150-9A9B-D865BA7F0A3CQ38983373-7D3AB345-C298-4C6A-AE09-601F768659B0Q39025929-E50DCCFE-9318-420E-B701-33C82BEC0478Q39328851-D4C54F05-446B-459F-AF3D-769F7DEB052EQ39440623-36FB2303-8490-4C28-9FC3-36650D22F7C9Q40718674-89953D9B-F551-4B06-8F25-5D2D5F83AFE4Q41233808-EDD8AE9C-1D68-4FBB-8A99-21EF00AC072CQ42014310-9423632D-0BE2-446C-9A7E-C248B620330DQ44415419-855B4419-F07D-4C27-8D83-956BDD466273Q45184859-06A30ED9-1AAD-49AB-8700-66895E607E9FQ50760839-DF4BACD8-40F6-4753-AE16-7C8AA990F10FQ51152045-979AD56E-4592-4DC7-88B5-28F85A58BFE3Q52597989-D764916A-AFB0-44AD-874E-FE2B6B64D223Q53117922-7776DEAE-7279-4D10-955A-AAC8B3284B18Q53221108-31D1FC54-91AE-402E-84B5-5D241FE5F59FQ53313117-CE208FD3-E229-41BB-B50B-9A27112CE436Q53362290-C5425E79-0831-46C3-A0DC-1A603E7F1064Q53474887-9379527D-D90B-4C76-8CFA-3F8F410CA12EQ53527367-B3149D31-C486-4AA1-8432-664CDB90F099Q53535022-730D4F6C-1E62-4DC4-BA2C-57575B3B0F7AQ53606514-62193D7A-D3FE-4447-B0ED-8B60686B122BQ54567821-49C540CE-65CB-46E2-A116-21A18518C8DCQ58550947-8B1A6BCC-47EF-4C0B-9147-FC6C9CD42778Q84364105-390EC148-F89F-4449-A8B7-527EF656D151Q84509645-3270E962-6103-4F68-A028-C7A4FA5EEF73Q85050862-5E276ED2-0336-4CA0-8B85-68E3C7AFAAC1Q85217666-E0AA91D7-1537-4778-B3F2-F7C48539F7DAQ87366541-B8A9E9E4-4BCA-456B-8033-5849D9556DCFQ91311500-D470F935-336F-4D65-B6E1-330893E215AF
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
S Ting
@en
S Ting
@nl
type
label
S Ting
@en
S Ting
@nl
prefLabel
S Ting
@en
S Ting
@nl
P31
P496
0000-0003-1415-7714